Plasma Homocysteine Concentrations in the Acute Phase After Central Retinal Vein Occlusion in a Chinese Population

References

• Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049–1057
   PubMed Web of Science ®Google Scholar
• Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–236
   PubMed Web of Science ®Google Scholar
• Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015–2022
   PubMed Web of Science ®Google Scholar
• Kloppenborg RP, Nederkoorn PJ, van der Graaf Y, Geerlings MI. Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study. Atherosclerosis 2011;216:461–466
   PubMed Web of Science ®Google Scholar
• Asfar S, Safar HA. Homocysteine levels and peripheral arterial occlusive disease: a prospective cohort study and review of the literature. J Cardiovasc Surg 2007;48:601–605
   Google Scholar
• Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011;118:119–133
   PubMed Web of Science ®Google Scholar
• Sodi A, Giambene B, Marcucci R, Sofi F, Fedi S, Abbate R, et al. Atherosclerotic and thrombophilic risk factors in patients with ischemic central retinal vein occlusion. Retina 2011;31:724–729
   PubMed Web of Science ®Google Scholar
• Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000;129:640–644
   Google Scholar
• Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: a population-based study. Am J Ophthalmol 2005;139:181–182
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, Al-Attas OS. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol 2002;12:495–500
   Google Scholar
• Ferrazzi P, Di Micco P, Quaglia I, Rossi LS, Bellatorre AG, Gaspari G, et al. Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion. Thromb J 2005;3:13 . doi: 10.1186/1477-9560-3-13
   PubMedGoogle Scholar
• Yildirim C, Yaylali V, Tatlipinar S, Kaptanoğlu B, Akpinar S. Hyperhomocysteinemia: a risk factor for retinal vein occlusion. Ophthalmologica 2004;218:102–106
   PubMed Web of Science ®Google Scholar
• Weger M, Stanger O, Deutschmann H, Temmel W, Renner W, Schmut O, et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:286–290
   PubMed Web of Science ®Google Scholar
• Cahill M, Karabatzaki M, Donoghue C, Meleady R, Mynett-Johnson LA, Mooney D, et al. Thermolabile MTHFR genotype and retinal vascular occlusive disease. Br J Ophthalmol 2001;85:88–90
   PubMed Web of Science ®Google Scholar
• Martin SC, Rauz S, Marr JE, Martin N, Jones AF, Dodson PM. Plasma total homocysteine and retinal vascular disease. Eye 2000;14:590–593
   Google Scholar
• Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina 1981;1:27–55
   PubMedGoogle Scholar
• Lattanzio R, Sampietro F, Ramoni A, Fattorini A, Brancato R, D’Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina 2006;26:65–70
   Google Scholar
• Moghimi S, Najmi Z, Faghihi H, Karkhaneh R, Farahvash MS, Maghsoudipour M. Hyperhomocysteinemia and central retinal vein occlusion in Iranian population. Int Ophthalmol 2008;28:23–28
   Google Scholar
• Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003;136:1136–1150
   PubMed Web of Science ®Google Scholar
• Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005;93:1021–1026
   PubMed Web of Science ®Google Scholar
• McGimpsey SJ, Woodside JV, Cardwell C, Cahill M, Chakravarthy U. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 2009;116:1778–1787
   PubMed Web of Science ®Google Scholar
• Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001;85:1313–1315
   PubMed Web of Science ®Google Scholar
• Pianka P, Almog Y, Man O, Goldstein M, Sela BA, Loewenstein A. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000;107:1588–1592
   PubMed Web of Science ®Google Scholar
• Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 2000;78:340–343
   PubMedGoogle Scholar
• Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F. Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci 2006;47:4067–4071
   PubMed Web of Science ®Google Scholar
• McGimpsey SJ, Woodside JV, Bamford L, Gilchrist SE, Graydon R, McKeeman GC, et al. Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci 2005;46:4712–4716
   PubMed Web of Science ®Google Scholar
• Di Crecchio L, Parodi MB, Sanguinetti G, Iacono P, Ravalico G. Hyperhomocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology 2004;111:940–945
   PubMedGoogle Scholar
• Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536–545
   PubMed Web of Science ®Google Scholar
• Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–113
   PubMed Web of Science ®Google Scholar
• Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991;565:441–566
   PubMed Web of Science ®Google Scholar
• Marcucci R, Giusti B, Betti I, Evangelisti L, Fedi S, Sodi A, et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res 2003;110:7–12
   Google Scholar
• Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function. Curr Drug Metab 2005;6:27–36
   PubMed Web of Science ®Google Scholar
• Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr 2006;136:1741S–1749S
   PubMed Web of Science ®Google Scholar
• Mujumdar VS, Hayden MR, Tyagi SC. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 2000;183:28–36
   PubMed Web of Science ®Google Scholar
• Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36–37
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407–413
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Homocysteine and stroke. Curr Opin Neurol 2001;14:95–102
   PubMed Web of Science ®Google Scholar
• Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988;43:414–421
   PubMed Web of Science ®Google Scholar
• Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3–32
   PubMed Web of Science ®Google Scholar
• Vine AK. Hyperhomocysteinemia: a new risk factor for central retinal vein occlusion. Trans Am Ophthalmol Soc 2000;98:493–503
   PubMedGoogle Scholar
• Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001;86:772–776
   PubMed Web of Science ®Google Scholar
• Howard VJ, Sides EG, Newman GC, Cohen SN, Howard G, Malinow MR, et al. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke 2002;33:473–478
   PubMed Web of Science ®Google Scholar
• Al-Obaidi MK, Stubbs PJ, Amersey R, Noble MI. Acute and convalescent changes in plasma homocysteine concentrations in acute coronary syndromes. Heart 2001;85:380–384
   Google Scholar
• Gao W, Wang YS, Zhang P, Wang HY. Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol 2006;244:1246–1249
   PubMedGoogle Scholar
• Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Homocysteine and essential hypertension. J Clin Pharmacol 2003;43:1299–1306
   PubMed Web of Science ®Google Scholar